Lars Fruergaard Jørgensen, Novo Nordisk CEO (Photographer: Christopher Goodney/Bloomberg via Getty Images)
March 20, 2023 02:31 PM EDTUpdated March 21, 03:32 PM
Pharma
Manufacturing
Marketing

Most dos­es of No­vo Nordisk's Ozem­pic are re­moved from FDA drug short­age list af­ter sup­ply is­sues

Nicole DeFeudis

Editor

No­vo Nordisk’s type 2 di­a­betes treat­ment Ozem­pic, which is al­so used off-la­bel for weight loss, is back in stock fol­low­ing a months-long short­age, ac­cord­ing to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

David Ep­stein gets $140M for Ot­ti­mo's bi­func­tion­al take on hot PD-1xVEGF field

Roche’s Parkin­son’s drug flunks sec­ond mid-stage tri­al

Sang­amo strikes an­oth­er brain-tar­get­ing AAV part­ner­ship, this time with Astel­las

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Ex­clu­sive: Col­or Health alums raise $10M for new start­up, us­ing AI for reg­u­la­to­ry work

A service from the Financial Times